Recent Updates — PPBT

The Board of Directors appointed Mr. Isaac Israel, a director and former Chief Executive Officer, to serve as Interim Chief Executive Officer effective October 5, 2026, pending the selection of a permanent replacement. Concurrently, outgoing CEO Gil Efron transitions to Executive Director, Head of Corporate Development, while remaining on the Board. Mr. Israel previously led the company from 2012 to 2022 and served as Acting CEO in 2023. Purple Biotech Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and inflammatory diseases.

Purple Biotech Ltd. filed a Form 6-K on August 10, 2026, to furnish its updated corporate presentation dated August 2026. The filing highlights the company's financial position as of June 30, 2026, reporting $6.1 million in cash and a projected runway extending to mid-2027. It outlines the development pipeline for lead candidate IM1240, a tri-specific antibody expected to enter clinical trials in 2027, alongside preclinical data for other programs including CM24 and NT219. The presentation details safety and efficacy results from IND-enabling studies and Phase 2 proof-of-concept data for CM24 in pancreatic cancer. Purple Biotech Ltd. operates in the biotechnology industry, focusing on developing immuno-oncology therapies.

Purple Biotech Ltd. reported second quarter 2026 financial results on August 7, 2026. The company held $6.1 million in cash as of June 30, 2026, providing a runway through mid-2027. R&D expenses rose to $0.7 million from $0.6 million year-over-year, while G&A decreased to $0.6 million from $0.7 million. Operating loss was $1.3 million compared to $1.2 million in the prior period. Net income turned positive at $0.4 million due to a non-cash gain from warrant revaluation, contrasting with a net loss of $1.1 million previously. The company presented new preclinical data for IM1240 at EACR 2026 and plans to enter clinical studies in 2027. Purple Biotech Ltd. is a clinical-stage biotechnology company developing next-generation immunotherapy platforms.